Kekule Pharma Limited has appointed Paresh J. Prajapati as its Chief Commercial Officer (CCO), marking a strategic move to reinforce the company’s commercial leadership and growth agenda.

In his new role, Prajapati will be responsible for driving end-to-end commercial strategy, including sales performance, market expansion, customer engagement, and revenue acceleration, aligned with Kekule Pharma’s long-term business objectives. His appointment comes at a time when pharmaceutical companies are sharpening their focus on scale, operational efficiency, and competitive differentiation across domestic and global markets.

Prajapati brings extensive leadership experience in pharmaceutical and healthcare commercial operations, having worked across key functions such as sales leadership, business development, go-to-market strategy, and channel management. Over the course of his career, he has contributed to building high-impact commercial teams, strengthening distributor networks, and executing data-driven growth initiatives across diverse therapy areas.

Known for his execution-focused leadership style and market insight, Prajapati is expected to play a pivotal role in strengthening Kekule Pharma’s commercial footprint and driving sustainable value creation.

His appointment underscores the company’s commitment to investing in seasoned leadership to support its next phase of growth.